On 10 May, Cortexyme, a clinical-stage pharmaceutical company developing novel treatments for altering the course of Alzheimer’s disease (AD) and other neurodegenerative disorders, provided an update on expected clinical data readouts and reported first quarter 2021 financial results.
The GAIN Trial is a Phase II/III randomised, double-blind and placebo-controlled study that is evaluating the efficacy, safety and tolerability of two dose levels of COR388 oral capsules in people with mild to moderate AD. The trial has enrolled 643 participants in the US, France, Spain, Poland, Netherlands and UK and approximately one-third of participants are pending completion in the study. The fully enrolled GAIN Phase II/III trial will continue as planned, participants with mild to moderate AD will continue to receive the study drug at their assigned dose, with top-line results expected in the fourth quarter of 2021. The company plans to present baseline data from the GAIN trial at upcoming conferences.
https://www.cortexyme.com/cortexyme-provides-business-update-and-reports-first-quarter-2021-results/